Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Oktober 2021 08:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech to Participate in the Virtual Solebury Trout Fall Private Company Showcase Co-hosted with BMO

SANTA ANA, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body’s immune system through the development of Natural Killer (NK) cell...
04. Oktober 2021 08:00 ET | Quelle: NKGen Biotech, Inc.

NKMax Announces SNK01 Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

SANTA ANA, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies,...
15. April 2021 08:30 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer

SANTA ANA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
13. April 2021 09:30 ET | Quelle: NKGen Biotech, Inc.

NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC

SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies,...
07. April 2021 09:00 ET | Quelle: NKGen Biotech, Inc.

NKGen Biotech Announces Appointment of Philip Moody as Chief Financial Officer

SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
02. April 2021 06:30 ET | Quelle: NKGen Biotech, Inc.

NKMax America Announces Corporate Name Change to NKGen Biotech

SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
04. Februar 2021 08:00 ET | Quelle: NKMax America

NKMax America Announces Key Leadership Appointment

SANTA ANA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
20. Oktober 2020 06:30 ET | Quelle: NKMax America

Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumorsPre-clinical...
08. September 2020 19:00 ET | Quelle: NKMax America

NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer

SANTA ANA, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
31. August 2020 14:21 ET | Quelle: NKMax America

NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors

SANTA ANA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's innate immune system through the development of Natural Killer (NK)...

Vorherige Seite

Nächste Seite